Is Kazia’s paxalisib becoming the new backbone for checkpoint combos?

By on    Pharma & Biotech  

Is Kazia’s paxalisib becoming the new backbone for checkpoint combos?

Kazia Therapeutics Limited has presented new clinical and translational data at the 2025 San Antonio Breast Cancer Symposium demonstrating that paxalisib, its investigational brain-penetrant PI3K/mTOR inhibitor, may suppress circulating tumor cell clusters and reverse immune exhaustion in two of the most treatment-resistant breast cancer subtypes—HER2-positive metastatic breast cancer and triple-negative breast cancer. The early evidence, […]

Can next-gen immunotherapy combos finally crack the code in metastatic breast cancer?

By on    Features & Analysis  

Can next-gen immunotherapy combos finally crack the code in metastatic breast cancer?

The landscape of metastatic breast cancer treatment is facing a fundamental rethink, with the oncology field laser-focused on one of its greatest clinical challenges: how to break immune resistance and stop metastatic spread. Despite a wave of checkpoint inhibitor approvals and initial enthusiasm, progress in metastatic breast cancer—especially for subtypes like triple-negative and HER2-positive disease—has […]